Enicepatide also reduced HbA1c by 2.65 percentage points at the highest dose after 48 weeks, with Roche saying weight loss had not yet plateaued as it advances Phase 3 studies of the experimental treatment.
Enicepatide also reduced HbA1c by 2.65 percentage points at the highest dose after 48 weeks, with Roche saying weight loss had not yet plateaued as it advances Phase 3 studies of the experimental treatment.